View ValuationCore Laboratories 将来の成長Future 基準チェック /26Core Laboratoriesは、18.3%と2.5%でそれぞれ年率18.3%で利益と収益が成長すると予測される一方、EPSはgrowで18.5%年率。主要情報18.3%収益成長率18.51%EPS成長率Energy Services 収益成長7.8%収益成長率2.5%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日18 May 2026今後の成長に関する最新情報お知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.お知らせ • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.お知らせ • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.お知らせ • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.お知らせ • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.すべての更新を表示Recent updatesお知らせ • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.お知らせ • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United Statesお知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.お知らせ • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.お知らせ • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026お知らせ • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.お知らせ • Oct 01Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda.Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025. This acquisition will further enhance Core Lab’s presence to deliver the most comprehensive suite of reservoir laboratory services in the region and long-term, sustainable value for its clients and shareholders. Core Laboratories Inc. (NYSE:CLB) completed the acquisition of Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025.お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2025 Results on Oct 22, 2025Core Laboratories Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025お知らせ • Jul 24+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 25, 2025On July 23, 2025, Core Laboratories Inc. Board approved a cash dividend of $0.01 per share of common stock payable on August 25, 2025, to shareholders of record on August 4, 2025.お知らせ • Jun 30+ 3 more updatesCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth IndexCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth Indexお知らせ • Jun 25Core Laboratories Inc. to Report Q2, 2025 Results on Jul 23, 2025Core Laboratories Inc. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025お知らせ • Apr 24Core Laboratories Inc. Approves Cash Dividend, Payable on May 27, 2025On April 23, 2025, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 27, 2025, to shareholders of record on May 5, 2025.お知らせ • Apr 02Core Laboratories Inc., Annual General Meeting, May 21, 2025Core Laboratories Inc., Annual General Meeting, May 21, 2025. Location: at the hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United Statesお知らせ • Mar 25Core Laboratories Inc. to Report Q1, 2025 Results on Apr 23, 2025Core Laboratories Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2025お知らせ • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.お知らせ • Jan 04Core Laboratories Inc. to Report Q4, 2024 Results on Jan 29, 2025Core Laboratories Inc. announced that they will report Q4, 2024 results After-Market on Jan 29, 2025Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 7x in the Energy Services industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.65 per share.Declared Dividend • Oct 28Third quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 4th November 2024 Payment date: 25th November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 4%.Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.20 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (up from US$0.20 in 3Q 2023). Revenue: US$134.4m (up 7.2% from 3Q 2023). Net income: US$11.7m (up 27% from 3Q 2023). Profit margin: 8.7% (up from 7.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.Buy Or Sell Opportunity • Oct 23Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €15.90. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 123% in the next 2 years.お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024Core Laboratories Inc. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024Buy Or Sell Opportunity • Aug 06Now 43% undervaluedThe stock has been flat over the last 90 days, currently trading at €12.30. The fair value is estimated to be €21.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.Upcoming Dividend • Jul 31Upcoming dividend of US$0.01 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 26 August 2024. Payout ratio is a comfortable 7.9% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.8%).Declared Dividend • Jul 31Second quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 5th August 2024 Payment date: 26th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 6%.お知らせ • Jul 25+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024On July 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on August 26, 2024 to shareholders of record on August 5, 2024.お知らせ • Jun 26Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024Core Laboratories Inc. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024Declared Dividend • Apr 29First quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 3rd May 2024 Payment date: 28th May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 9%.お知らせ • Apr 26Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024On April 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 28, 2024 to shareholders of record on May 6, 2024.Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.068 (vs US$0.051 in 1Q 2023)First quarter 2024 results: EPS: US$0.068 (up from US$0.051 in 1Q 2023). Revenue: US$129.6m (up 1.0% from 1Q 2023). Net income: US$3.22m (up 36% from 1Q 2023). Profit margin: 2.5% (up from 1.8% in 1Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • Mar 26Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024Core Laboratories Inc. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024お知らせ • Mar 20Core Laboratories Inc., Annual General Meeting, May 08, 2024Core Laboratories Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Hotel Zaza, Memorial City, 9787 Katy Freeway Houston Texas United States Agenda: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified; to ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024; to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis, and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables; and to discuss other matters.お知らせ • Feb 01+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024On January 31, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on March 4, 2024 to shareholders of record on February 12, 2024.お知らせ • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.お知らせ • Oct 05Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023Core Laboratories Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.15 in 2Q 2022)Second quarter 2023 results: EPS: US$0.49 (up from US$0.15 in 2Q 2022). Revenue: US$127.9m (up 5.8% from 2Q 2022). Net income: US$22.8m (up 223% from 2Q 2022). Profit margin: 18% (up from 5.8% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 04Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I DirectorCore Laboratories Inc. announced at the AGM held on June 28, 2023 that the company approved to elect Curtis Anastasio as Class I Director.お知らせ • Jun 28Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023Core Laboratories Inc. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023業績と収益の成長予測DB:HJ1 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202754837N/AN/A212/31/202652121N/AN/A13/31/2026525291834N/A12/31/2025527302237N/A9/30/2025518323450N/A6/30/2025517303954N/A3/31/2025518284458N/A12/31/2024524314356N/A9/30/2024523264455N/A6/30/2024514243042N/A3/31/2024511382233N/A12/31/2023510371425N/A9/30/202350941919N/A6/30/2023510391525N/A3/31/202350324616N/A12/31/2022490191525N/A9/30/202248715619N/A6/30/202247991125N/A3/31/2022477102134N/A12/31/2021470202337N/A9/30/202145931518N/A6/30/2021446331526N/A3/31/2021443193244N/A12/31/2020487-974558N/A9/30/2020530-1017791N/A6/30/2020598-807996N/A3/31/2020651-556686N/A12/31/201966894N/A90N/A9/30/201968592N/A106N/A6/30/201969490N/A104N/A3/31/201970096N/A114N/A12/31/201870180N/A112N/A9/30/201869893N/A120N/A6/30/201867891N/A126N/A3/31/201866187N/A118N/A12/31/201764881N/A124N/A9/30/201762775N/A102N/A6/30/201760871N/A107N/A3/31/201759867N/A116N/A12/31/201659065N/A132N/A9/30/201662864N/A158N/A6/30/201668281N/A167N/A3/31/201673899N/A186N/A12/31/2015798115N/A219N/A9/30/2015893166N/A268N/A6/30/2015972199N/A299N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: HJ1の予測収益成長率 (年間18.3% ) は 貯蓄率 ( 1.9% ) を上回っています。収益対市場: HJ1の収益 ( 18.3% ) はGerman市場 ( 16.9% ) よりも速いペースで成長すると予測されています。高成長収益: HJ1の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: HJ1の収益 ( 2.5% ) German市場 ( 6.8% ) よりも低い成長が予測されています。高い収益成長: HJ1の収益 ( 2.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: HJ1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YEnergy 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 00:19終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Core Laboratories Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関James WestBarclaysNicholas GreenBernsteinSaurabh PantBofA Global Research27 その他のアナリストを表示
お知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.
お知らせ • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.
お知らせ • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.
お知らせ • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.
お知らせ • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.
お知らせ • May 02Core Laboratories Inc. Approves Cash Dividend, Payable on June 1, 2026Core Laboratories Inc. announced on April 29, 2026, the Board approved a cash dividend of $0.01 per share of common stock, payable on June 1, 2026, to shareholders of record on May 11, 2026.
お知らせ • Apr 01Core Laboratories Inc., Annual General Meeting, May 12, 2026Core Laboratories Inc., Annual General Meeting, May 12, 2026. Location: hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
お知らせ • Mar 24+ 1 more updateCore Laboratories Inc. Revises Earnings Guidance for the First Quarter 2026Core Laboratories Inc. revised earnings guidance for the first quarter 2026 . Company continues to evaluate and monitor the evolving geopolitical conflict in the Middle East and its effect on the Company's first quarter 2026 financial results. Core Lab is working with clients and its local teams to manage operations and mitigate impacts on project execution through a rapidly changing operating environment. The safety and security of the Company's employees remain its highest priority. At this time, due to regional instability, including client-driven project delays, travel constraints, and supply-chain disruptions, the Company expects first quarter 2026 revenue and earnings to be below its previously issued guidance provided on February 4, 2026. Changes in client activity levels across the Middle East are directly impacting operations in the countries where Core Lab operates. Damage to oil refining infrastructure and storage terminals has created capacity limitations, forcing operators to shut in or limit oil production. These effects have extended to regional supply chains and the maritime transportation of crude oil and refined products—particularly through the Strait of Hormuz—resulting in logistical constraints and delays in project execution. The impact has been more pronounced in Reservoir Description due to its unique role in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization, all of which rely on predictable field access, sample movement, and laboratory operations. Production Enhancement has been comparatively less affected; however, shipments of energetics products into certain parts of the region have been delayed or temporarily suspended. Core's revised guidance for first quarter 2026 revenue ranges from $119,000,000to $123,000,000, while operating income, ex-items, is projected to range from $5,700,000to $7,100,000. The Company is now projecting Earnings Per Share, ex-items, to be between $0.05 to $0.07 for the first quarter of 2026.
お知らせ • Mar 04Core Laboratories Inc. announced delayed annual 10-K filingOn 03/03/2026, Core Laboratories Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 05Core Laboratories Inc. Approves a Cash Dividend, Payable on March 9, 2026On February 4, 2026, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock, payable on March 9, 2026, to shareholders of record on February 16, 2026.
お知らせ • Jan 06Core Laboratories Inc. to Report Q4, 2025 Results on Feb 04, 2026Core Laboratories Inc. announced that they will report Q4, 2025 results After-Market on Feb 04, 2026
お知らせ • Oct 23+ 1 more updateCore Laboratories Inc. Announces Earnings Guidance for Fourth Quarter 2025Core Laboratories Inc. announced earnings guidance for fourth quarter 2025. For the quarter, revenue is projected to range from $132,000,000 to $136,000,000, with operating income of $14,000,000 to $16,100,000, yielding operating margins of approximately 11%. EPS for the fourth quarter of 2025 is expected to be $0.18 to $0.22.
お知らせ • Oct 01Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda.Core Laboratories Inc. (NYSE:CLB) acquired Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025. This acquisition will further enhance Core Lab’s presence to deliver the most comprehensive suite of reservoir laboratory services in the region and long-term, sustainable value for its clients and shareholders. Core Laboratories Inc. (NYSE:CLB) completed the acquisition of Solintec Consultoria E Servicos De Geologia Ltda on September 30, 2025.
お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2025 Results on Oct 22, 2025Core Laboratories Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
お知らせ • Jul 24+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 25, 2025On July 23, 2025, Core Laboratories Inc. Board approved a cash dividend of $0.01 per share of common stock payable on August 25, 2025, to shareholders of record on August 4, 2025.
お知らせ • Jun 30+ 3 more updatesCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth IndexCore Laboratories Inc.(NYSE:CLB) dropped from Russell 2000 Growth Index
お知らせ • Jun 25Core Laboratories Inc. to Report Q2, 2025 Results on Jul 23, 2025Core Laboratories Inc. announced that they will report Q2, 2025 results After-Market on Jul 23, 2025
お知らせ • Apr 24Core Laboratories Inc. Approves Cash Dividend, Payable on May 27, 2025On April 23, 2025, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 27, 2025, to shareholders of record on May 5, 2025.
お知らせ • Apr 02Core Laboratories Inc., Annual General Meeting, May 21, 2025Core Laboratories Inc., Annual General Meeting, May 21, 2025. Location: at the hotel zaza, memorial city, 9787 katy freeway, texas 77024, houston, United States
お知らせ • Mar 25Core Laboratories Inc. to Report Q1, 2025 Results on Apr 23, 2025Core Laboratories Inc. announced that they will report Q1, 2025 results at 4:00 PM, US Eastern Standard Time on Apr 23, 2025
お知らせ • Jan 30+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the First Quarter 2025Core Laboratories Inc. provided earnings revenue for the first quarter 2025. The Company's first quarter 2025 revenue is projected to range from $121,000,000 to $127,000,000, with operating income of $10,200,000 to $12,800,000, yielding operating margins of approximately 9%. As such, EPS for the first quarter of 2025 is expected to be $0.12 to $0.16.
お知らせ • Jan 04Core Laboratories Inc. to Report Q4, 2024 Results on Jan 29, 2025Core Laboratories Inc. announced that they will report Q4, 2024 results After-Market on Jan 29, 2025
Valuation Update With 7 Day Price Move • Nov 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €20.20, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 7x in the Energy Services industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.65 per share.
Declared Dividend • Oct 28Third quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 4th November 2024 Payment date: 25th November 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 7%. Cash payout ratio: 4%.
Reported Earnings • Oct 24Third quarter 2024 earnings released: EPS: US$0.25 (vs US$0.20 in 3Q 2023)Third quarter 2024 results: EPS: US$0.25 (up from US$0.20 in 3Q 2023). Revenue: US$134.4m (up 7.2% from 3Q 2023). Net income: US$11.7m (up 27% from 3Q 2023). Profit margin: 8.7% (up from 7.4% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Oct 24+ 1 more updateCore Laboratories Inc. Provides Earnings Guidance for the Fourth Quarter of 2024Core Laboratories Inc. provided earnings guidance for the fourth quarter of 2024. The company’s fourth quarter 2024 revenue is projected to range from $128,500,000 to $135,500,000, with operating income of $14,800,000 to $17,700,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2024 is expected to be $0.20 to $0.25.
Buy Or Sell Opportunity • Oct 23Now 23% undervaluedThe stock has been flat over the last 90 days, currently trading at €15.90. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 11% in 2 years. Earnings are forecast to grow by 123% in the next 2 years.
お知らせ • Sep 25Core Laboratories Inc. to Report Q3, 2024 Results on Oct 23, 2024Core Laboratories Inc. announced that they will report Q3, 2024 results After-Market on Oct 23, 2024
Buy Or Sell Opportunity • Aug 06Now 43% undervaluedThe stock has been flat over the last 90 days, currently trading at €12.30. The fair value is estimated to be €21.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 16%. For the next 3 years, revenue is forecast to grow by 4.5% per annum. Earnings are also forecast to grow by 20% per annum over the same time period.
Upcoming Dividend • Jul 31Upcoming dividend of US$0.01 per shareEligible shareholders must have bought the stock before 05 August 2024. Payment date: 26 August 2024. Payout ratio is a comfortable 7.9% and this is well supported by cash flows. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (3.8%).
Declared Dividend • Jul 31Second quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 5th August 2024 Payment date: 26th August 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 8%. Cash payout ratio: 6%.
お知らせ • Jul 25+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on August 26, 2024On July 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on August 26, 2024 to shareholders of record on August 5, 2024.
お知らせ • Jun 26Core Laboratories Inc. to Report Q2, 2024 Results on Jul 24, 2024Core Laboratories Inc. announced that they will report Q2, 2024 results After-Market on Jul 24, 2024
Declared Dividend • Apr 29First quarter dividend of US$0.01 announcedShareholders will receive a dividend of US$0.01. Ex-date: 3rd May 2024 Payment date: 28th May 2024 Dividend yield will be 0.2%, which is lower than the industry average of 2.7%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 9%.
お知らせ • Apr 26Core Laboratories Inc. Approves Cash Dividend, Payable on May 28, 2024On April 24, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on May 28, 2024 to shareholders of record on May 6, 2024.
Reported Earnings • Apr 25First quarter 2024 earnings released: EPS: US$0.068 (vs US$0.051 in 1Q 2023)First quarter 2024 results: EPS: US$0.068 (up from US$0.051 in 1Q 2023). Revenue: US$129.6m (up 1.0% from 1Q 2023). Net income: US$3.22m (up 36% from 1Q 2023). Profit margin: 2.5% (up from 1.8% in 1Q 2023). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 1.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • Mar 26Core Laboratories Inc. to Report Q1, 2024 Results on Apr 24, 2024Core Laboratories Inc. announced that they will report Q1, 2024 results After-Market on Apr 24, 2024
お知らせ • Mar 20Core Laboratories Inc., Annual General Meeting, May 08, 2024Core Laboratories Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Hotel Zaza, Memorial City, 9787 Katy Freeway Houston Texas United States Agenda: To re-elect two current Class III Directors to serve under the terms and conditions described within the proxy statement until our annual meeting in 2027 and until their successors shall have been duly elected and qualified; to ratify the appointment of KPMG LLP as the Company's independent registered public accountants for the year ending December 31, 2024; to approve, on an advisory basis, the compensation philosophy, policies and procedures described in the section entitled Compensation Discussion and Analysis, and the compensation of the Company's named executive officers as disclosed pursuant to the U.S. Securities and Exchange Commission's compensation disclosure rules, including the compensation tables; and to discuss other matters.
お知らせ • Feb 01+ 1 more updateCore Laboratories Inc. Approves Cash Dividend, Payable on March 4, 2024On January 31, 2024, the Board of Core Laboratories Inc. approved a cash dividend of $0.01 per share of common stock payable on March 4, 2024 to shareholders of record on February 12, 2024.
お知らせ • Nov 02+ 1 more updateCore Laboratories Inc. Provides Consolidated Earnings Guidance for the Fourth Quarter of 2023Core Laboratories Inc. provided consolidated earnings guidance for the fourth quarter of 2023. The company's fourth quarter 2023 revenue is projected to range from $125,000,000 to $132,000,000 and operating income of $13,800,000 to $17,300,000, yielding operating margins of approximately 12%. EPS for the fourth quarter of 2023 is expected to be $0.17 to $0.23. The Company's fourth quarter 2023 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange.
お知らせ • Oct 05Core Laboratories Inc. to Report Q3, 2023 Results on Nov 01, 2023Core Laboratories Inc. announced that they will report Q3, 2023 results After-Market on Nov 01, 2023
Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.15 in 2Q 2022)Second quarter 2023 results: EPS: US$0.49 (up from US$0.15 in 2Q 2022). Revenue: US$127.9m (up 5.8% from 2Q 2022). Net income: US$22.8m (up 223% from 2Q 2022). Profit margin: 18% (up from 5.8% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Energy Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 04Core Laboratories Inc. Approves to Elect Curtis Anastasio as Class I DirectorCore Laboratories Inc. announced at the AGM held on June 28, 2023 that the company approved to elect Curtis Anastasio as Class I Director.
お知らせ • Jun 28Core Laboratories Inc. to Report Q2, 2023 Results on Jul 26, 2023Core Laboratories Inc. announced that they will report Q2, 2023 results After-Market on Jul 26, 2023